Navigation Links
Montana Passes Newborn Screening Law for Cystic Fibrosis
Date:1/17/2008

State Joins 36 Others in Screening for Life-Threatening, Genetic Disease

WASHINGTON, Jan. 17 /PRNewswire-USNewswire/ -- All newborns in Montana will be screened for cystic fibrosis (CF), beginning today. Montana is the 37th state in the country, plus the District of Columbia, to join the roster of states that support routine CF screening at birth.

"We congratulate Montana on joining a growing list of states dedicated to supporting newborn screening for cystic fibrosis," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "Early diagnosis for CF is critically important because it gives every newborn a better chance for better health and a longer life."

Cystic fibrosis is a fatal genetic disease that affects 30,000 children and adults in the United States. Newborn screening for cystic fibrosis is important because more than 10 million Americans are unknowing, symptomless carriers of a cystic fibrosis gene. And, most people who have a child with CF are not aware of a family history of the disease. Cystic fibrosis causes thick mucus to build up in the lungs and other organs, causing life-threatening infections and serious digestive complications.

Research studies show that newborn screening for CF will likely improve and extend the lives of those born with the disease. Early diagnosis allows affected infants to begin nutritional interventions immediately. In research studies, these interventions have been shown to improve height, weight, cognitive and lung function, and to reduce hospitalizations.

When the CF Foundation was created in 1955, few children lived to attend elementary school. Today, as a result of dramatic improvements in research and care, the median age of survival for a person with CF is 37 years. The CF Foundation strongly urges all states to implement comprehensive programs for routine newborn screening for cystic fibrosis.

About the Cystic Fibrosis Foundation <
'/>"/>

SOURCE Cystic Fibrosis Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Actress, Singer, Songwriter Miley Cyrus, Also Known as Hannah Montana, Adds St. Jude Math-A-Thon(R) Video Host to Her Talents
2. Montana State University researchers investigate new suspect in West Nile deaths of pelicans
3. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
4. TriWest and Montana VA Launch PTSD Video Conference to Reach Rural Health Care Providers
5. Montana Health Care Leader Elected Board Chair of National Association
6. Wearable Artificial Kidney Passes Test
7. ZONARE Surpasses 1000th Worldwide z.one Ultrasound System Shipment
8. Resolution Recognizing Pulmonary Fibrosis Challenges Overwhelmingly Passes House
9. AmeriCares Passes $7 Billion Mark in Aid Distributed
10. A Breath of Fresh Air From Washington: Senate Passes Historic Asbestos Ban
11. House of Representatives Passes Stop AIDS in Prison Act of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...on models are enhanced by taking into account risk...ity, according to research teams led by epidemiolo...ncer Center in two complementary papers appearing ...rch . , In the first study to focus on African-A...n increased exposure to certain risks. Based upon ...
(Date:9/4/2008)...wswire/ -- A groundbreaking program,dealing with t...atus of,men, their shorter life spans, unmet gende...ke place Wednesday, September 17 at White Plains,H... of the Westchester,medical and psychiatric societ... and Lionel Tiger, Ph.D., Dr. Legatto, an interna...
(Date:9/4/2008)...ivate Medicare Advantage (MA) plans will be paid a...ompared to what the same enrollee would have cost ...m, according to a new report from The Commonwealth... mandated by the Medicare Improvements for Patient...take effect beginning in 2010 had been fully in p...
(Date:9/4/2008)...ns may be shortchanging their golden years by tapp...University of Illinois expert who has studied the ... , More than three of every four Americans trim ...laiming benefits early, a choice many might forego...nd consequences, law professor Richard L. Kaplan s...
Breaking Medicine News(10 mins):Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3
... levels of stress experienced by children may hamp...n suffering from post-traumatic// stress disorder ... memory and emotion had become smaller in size. C...stress and anxiety when their hippocampus is shrun...
...in, say researchers at the Stanford University Sch...spital. The researchers found that children with p...he stress hormone cortisol were likely to experien...n structure important in memory processing and emo...
...on for health professionals must include teaching ...//cancer about sex, cancer experts say. Sexuality... want to discuss with their doctor or member of th...rn of the Cancer Council Victoria, and Dr Annette ...
...hat a new technique safely and effectively removes...t risk for pulmonary embolism and disability. Th...n to have a positive impact on patients’ quality o...in and swelling, as well as greatly improving thei...
Other Medicine News:Health News:Child Brain Likely To Be Harmed By Stress 2Health News:Severe PTSD Damages Children's Brains: Study 2Health News:Severe PTSD Damages Children's Brains: Study 3Health News:Sex After Cancer 2Health News:DVT Treatment Vacuums Away Blood Clots – Prevents Disabilit 2
(Date:9/4/2008)...- Southern Research Institute,today announced that...ted,the organization to participate in the newly-f...Network (MLPCN). The MLPCN -- a collaborative,rese... Program which is,designed to benefit human health... and validate future targets for drug discovery., ...
(Date:9/4/2008)...l activity and favorable safety .../- Idenix,Pharmaceuticals, ... engaged,in the discovery and development of drugs...ious diseases, today announced that it has complet... non-nucleoside reverse,transcriptase inhibitor (N...
(Date:9/3/2008)...ldren Studied. Wrong,Conclusions Reached., NIXA, ...for Disease,Control and Prevention (CDC) study rel...R vaccine and autism. The National Autism Associat...he growing public concern over a,vaccine-autism co...esign,and methodology., For years, parents have c...
(Date:9/3/2008)...sease Awareness Month, CHARLOTTESVILLE, Va., Sept... a clinical-stage drug-development company commerc...cal needs, announced today that it has begun,to en...s lead drug,candidate trans sodium crocetinate (TS...caltrials.gov Website, is investigating TSC as a t...
Breaking Medicine Technology:Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Heat stress influences low conception of dairy herds 288 1Heat stress influences low conception of dairy herds 288 2Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 1Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 2Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 3Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 4Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 5Youth Drug Use at a Five Year Low New Survey Shows 662 1Youth Drug Use at a Five Year Low New Survey Shows 662 2Youth Drug Use at a Five Year Low New Survey Shows 662 3Securians Minnesota Life Continues to Climb Group Life Rankings 658 1
...tudy Fails to Meet Primary Endpoint of Improvement... 2007 /PRNewswire-FirstCall/ --,Allos Therapeutics...H, the Company,s pivotal Phase 3 study of Efaproxy...y (WBRT) in women,with brain metastases originatin...its primary endpoint of demonstrating a,statistica...
...SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ --...l company committed to,the discovery, development ...reatment of hepatitis and cancer, announced today ...inical development as an,orally-administered direc... C virus (HCV) infection. , "We have identified a ...
Other Medicine Technology:Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 4
Aire-Cuf® and Fome-Cuf® tracheostomy tubes with talk attachment are available in I.D. sizes from 5.0 mm to 9.5 mm. , ,Developed to aid the ventilator dependent patient in communicating with
For additional patient safety, the laryngectomy tube is designed with an integral 15 mm ISO termination that can be connected to a ventilator, with or without the inner cannula in place , ,Portex&re
The all silicone construction of the shaft and neck flange provides the utmost in patient comfort. , ,The Aire-Cuf® tracheostomy tube offers a more traditional and familiar air-filled cuff desig
...® Mid-Range Aire-Cuf® Adjustable Neck Flan...he TTS™ tube except this tube features the m...g;., ,Adult Mid-Range Aire-Cuf® Adjustable Ne...ude a trach tie, disconnect wedge, and obturator/i...
Medicine Products: